Lincoln Pharma posts Rs 11.62 cr profit for Jan-Mar; revenue at Rs 161 cr
Lincoln Pharmaceuticals on Thursday reported a net profit of Rs 11.62 crore for the March quarter of 2024-25 and said it is building a portfolio in lifestyle and chronic segments,…
FDA panel debates COVID-19 vaccine recipe as questions swirl about fall shots
Government advisers are meeting Thursday to decide if COVID-19 vaccines need updating to improve protection this fall and winter – even as a new Trump administration policy has thrown into…
Bharat Bio successfully completes Phase III trials of new oral cholera vaccine Hillchol
HYDERABAD: Vaccine maker Bharat Biotech on Wednesday said its oral cholera vaccine, Hillchol, successfully completed Phase III clinical trials demonstrating efficacy against both Ogawa and Inaba serotypes. The Hyderabad-based vaccine…
55 drugs manufactured in Himachal found not of standard quality
Eight batches of a commonly used saline injections used to treat dehydration were found substandard along with 54 other drug samples manufactured by firms in Himachal in the monthly drug…
42 cos banned over supply of substandard drugs
Jaipur: The Rajasthan Medical Services Corporation (RMSC) Wednesday issued orders banning 42 pharma companies from supplying drugs as the samples were found to be substandard under the state govt’s free…
Gland Pharma Q4 results: Profit dips 3% YoY to ₹187 crore; 1800% dividend announced
Gland Pharma Q4 Results: Pharma company Gland Pharma on Tuesday, May 20, posted a weak set of numbers for the fourth quarter of the financial year 2024-25 (Q4 FY25), recording…
Medical shop operating without licence raided, illegal stock seized
A medical shop in Alwal was raided by officials of the Telangana Drugs Control Administration (DCA) following a tip-off about illegal sale of medicines. During the inspection, officials discovered that…
Zydus Wellness posts 30% profit growth in FY25, Q4 net sales up 17% YoY
For the quarter ended March 31, 2025, Zydus Wellness reported 17% year-on-year growth in net sales at ₹9,106 million, up from ₹7,780 million in Q4 FY24. Adjusted net profit after…
Lupin to boost complex generics in US, EU; eyes chronic growth in India
Lupin, which plans to develop the specialty business, is eyeing higher revenue share from its complex generics portfolios in the US and Europe. Moreover, with a pipeline of over 200…
Growth Triggers Line Up for Divi’s Labs
The stock of contract development and manufacturing organisation (CDMO) Divi’s Laboratories was among the top gainers in the BSE 100 index on Monday. It rose 4.81 per cent as its…
